Cargando…

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong

OBJECTIVE: To compare the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) and dipeptidyl peptidase-4 inhibitors (DPP4Is) on adverse outcomes in diabetic patients in Hong Kong. METHODS: This was a retrospective population-based cohort study of type 2 diabetes mellitus patients (n = 72,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sharen, Zhou, Jiandong, Leung, Keith Sai Kit, Wai, Abraham Ka Chung, Jeevaratnam, Kamalan, King, Emma, Liu, Tong, Wong, Wing Tak, Chang, Carlin, Wong, Ian Chi Kei, Cheung, Bernard Man Yung, Tse, Gary, Zhang, Qingpeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164005/ https://www.ncbi.nlm.nih.gov/pubmed/35142921 http://dx.doi.org/10.1007/s10557-022-07319-x

Ejemplares similares

Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
por: Mui, Jonathan V., et al.
Publicado: (2023)

Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users
por: Zhou, Jiandong, et al.
Publicado: (2022)

Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong
por: Lee, Sharen, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
por: Mui, Jonathan V., et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
por: Chung, Cheuk To, et al.
Publicado: (2023)

Territory-wide cohort study of Brugada syndrome in Hong Kong: predictors of long-term outcomes using random survival forests and non-negative matrix factorisation
por: Lee, Sharen, et al.
Publicado: (2021)

Predictive value of neutrophil‐to‐lymphocyte ratio for atrial fibrillation and stroke in type 2 diabetes mellitus: The Hong Kong Diabetes Study
por: Chang, Carlin, et al.
Publicado: (2022)

Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong
por: Au, Philip C. M., et al.
Publicado: (2023)

Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death
por: Lee, Sharen, et al.
Publicado: (2021)

Paediatric/young versus adult patients with long QT syndrome
por: Lee, Sharen, et al.
Publicado: (2021)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Territory-Wide Chinese Cohort of Long QT Syndrome: Random Survival Forest and Cox Analyses
por: Tse, Gary, et al.
Publicado: (2021)

Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019)

Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong
por: Zhou, Jiandong, et al.
Publicado: (2021)

Author Correction: Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong
por: Zhou, Jiandong, et al.
Publicado: (2022)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
por: Shaheer, Abid, et al.
Publicado: (2021)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Fragmented QRS Is Independently Predictive of Long-Term Adverse Clinical Outcomes in Asian Patients Hospitalized for Heart Failure: A Retrospective Cohort Study
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2021)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Risk stratification of cardiac arrhythmias and sudden cardiac death in type 2 diabetes mellitus patients receiving insulin therapy: A population‐based cohort study
por: Lee, Sharen, et al.
Publicado: (2021)

Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
por: Min, Se Hee, et al.
Publicado: (2018)

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
por: Wood, Stephen J, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
por: Foresta, Andreana, et al.
Publicado: (2023)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
por: Shoombuatong, Watshara, et al.
Publicado: (2015)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome
por: Kim, Kwang-il
Publicado: (2018)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019)

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
por: Yazbeck, R., et al.
Publicado: (2021)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study
por: Zhou, Jiandong, et al.
Publicado: (2021)

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis
por: Zhou, Jiandong, et al.
Publicado: (2022)

Identification of Novel SCN5A Single Nucleotide Variants in Brugada Syndrome: A Territory-Wide Study From Hong Kong
por: Tse, Gary, et al.
Publicado: (2020)

Synergistic effect of α‐glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment
por: Horikawa, Yukio, et al.
Publicado: (2010)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
por: Yassin, Sayf A, et al.
Publicado: (2017)

Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
por: Sütő, Gábor, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hhhq62ii5rjg6obu99rh2r6iok